Morgan Stanley analyst Maxwell Skor has maintained their bullish stance on CYTK stock, giving a Buy rating yesterday.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Maxwell Skor has given his Buy rating due to a combination of factors surrounding Cytokinetics’ recent clinical trial results and potential market impact. The company’s Phase 3 MAPLE-HCM trial demonstrated that aficamten, when used as a monotherapy, significantly improved peak oxygen uptake in patients with symptomatic obstructive hypertrophic cardiomyopathy compared to the standard beta blocker, metoprolol. This positive outcome, along with favorable safety data, suggests that aficamten could become a preferred treatment option for this condition.
Furthermore, the trial results are expected to support a supplemental New Drug Application, which could lead to initial approval by the end of 2025. Skor also notes the importance of understanding payer dynamics and the potential for aficamten to be a frontline treatment despite the low cost of existing beta blockers. These factors contribute to the optimism surrounding Cytokinetics’ stock and justify the Buy rating.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $120.00 price target.
Based on the recent corporate insider activity of 166 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CYTK in relation to earlier this year.